Skip to content

US · URGN · BIOTECHNOLOGY

UroGen Pharma Ltd. (URGN) intrinsic value and stock valuation

$27.65as of 2026-11-21 · Mkt cap 2.26B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

UroGen Pharma Ltd. DCF and intrinsic value

InvestorsCraft values URGN with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from URGN’s statements →

UroGen Pharma Ltd. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Princeton, NJ 08540 urogen.com

How the business is doing

Fiscal 2013–2025, USD

Revenue
$109.8M+56.2% 5y CAGRd
20132025
Net income
-$-153.49M
20132025
Free cash flow
-$-162.73M
20132025
Total equity
-$-105.47M
20132025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2013–2025, USD
20252024202320222021
Revenue$109.8M$90.4M$82.7M$64.4M$48M
Operating income-$-124.86M-$-96.78M-$-65.54M-$-79.04M-$-92.29M
Net income-$-153.49M-$-126.87M-$-102.24M-$-109.78M-$-110.82M
EPSd-$-3.19M-$-2.96M-$-3.55M-$-4.81M-$-4.96M
Operating cash flow-$-162.44M-$-96.77M-$-76.38M-$-87.56M-$-84.89M
Capital expenditure-$-290K-$-290K-$-190K-$-250K-$-750K
Free cash flow-$-162.73M-$-97.06M-$-76.57M-$-87.81M-$-85.64M
Total assets$200.5M$285.7M$178.3M$135.6M$119.8M
Total debt$128.3M$123.4M$99.4M$99.1M$400K
Net debt$17.6M-$-48.6M$4.39M$43.7M-$-43.96M
Total equity-$-105.47M-$-8.8M-$-65.21M-$-89.36M$8.41M
Cash and short-term investments$120.5M$236.7M$137M$100M$89.1M
Income statement
20252024202320222021
Revenue$109.8M$90.4M$82.7M$64.4M$48M
Cost of revenue$12.5M$8.88M$9.36M$7.65M$5.16M
Gross profit$97.3M$81.5M$73.4M$56.7M$42.9M
Research and development expenses$67.1M$57.2M$45.6M$52.9M$47.6M
Selling, general and administrative expenses$155.1M$0.00$93.3M$82.8M$0.00
Other expenses$0.00$121.2M$0.00$0.00$87.5M
Operating expenses$222.2M$178.3M$138.9M$135.7M$135.2M
Cost and expenses$234.7M$187.2M$148.3M$143.4M$140.3M
Interest income$5.96M$8.9M$2.64M$940K$360K
Interest expense$33.9M$12.5M$14.7M$8.44M$17.4M
Depreciation and amortization$2.41M$330K$1.71M$1.82M$830K
Ebitda-$-135.66M-$-95.35M-$-60.35M-$-76.21M-$-108.54M
Operating income-$-124.86M-$-96.78M-$-65.54M-$-79.04M-$-92.29M
Total other income/expenses, net-$-28.55M-$-27.26M-$-32.79M-$-28.99M-$-17.08M
Income before tax-$-153.42M-$-124.04M-$-98.32M-$-108.03M-$-109.37M
Income tax expense$80K$2.83M$3.92M$1.75M$1.45M
Net income-$-153.49M-$-126.87M-$-102.24M-$-109.78M-$-110.82M
Weighted average shares outstanding$48.1M$42.9M$28.8M$22.8M$22.4M
Weighted average diluted shares outstanding$48.1M$42.9M$28.8M$22.8M$22.4M
Balance sheet
20252024202320222021
Cash and short-term investments$120.5M$236.7M$137M$100M$89.1M
Net receivables$33.1M$20.3M$15.4M$12.7M$11.7M
Inventory$16.5M$9.23M$5.67M$4.33M$4.83M
Total current assets$186M$276.1M$169.2M$128.9M$114.4M
Property, plant and equipment, net$9.09M$3.79M$2.36M$3.75M$3.15M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$180K$5.02M$4.5M$0.00$680K
Total non-current assets$14.4M$9.58M$9.12M$6.71M$5.36M
Total assets$200.5M$285.7M$178.3M$135.6M$119.8M
Accounts payable$12.1M$10.9M$6.51M$5.53M$5.79M
Short-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$46.4M$46M$31.2M$23.9M$22.4M
Long-term debt$128.3M$123.4M$99.4M$99.1M$400K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$259.5M$248.6M$212.3M$201.1M$89M
Capital lease obligations$6.12M$1.65M$840K$1.59M$400K
Total liabilities$305.9M$294.5M$243.5M$225M$111.3M
Common stock$130K$120K$90K$60K$60K
Retained earnings-$-959.72M-$-806.22M-$-679.35M-$-577.1M-$-467.32M
Accumulated other comprehensive income (loss)$20K$60K$10K-$-110K-$-30K
Total equity-$-105.47M-$-8.8M-$-65.21M-$-89.36M$8.41M
Total investments$9.89M$69.7M$46.5M$44.6M$45.5M
Total debt$128.3M$123.4M$99.4M$99.1M$400K
Net debt$17.6M-$-48.6M$4.39M$43.7M-$-43.96M
Cash flow statement
20252024202320222021
Net income-$-153.49M-$-126.87M-$-102.24M-$-109.78M-$-110.82M
Depreciation and amortization$2.41M$1.19M$1.71M$1.82M$1.77M
Stock-based compensation$12M$13.1M$9.34M$10.6M$23.1M
Change in working capital-$-27.91M$4.93M$3.34M-$-6.31M-$-13.11M
Accounts receivable-$-12.78M-$-4.86M-$-2.74M-$-990K-$-4.67M
Inventory-$-7.24M-$-3.55M-$-1.35M-$-360K-$-2.87M
Accounts payable$290K$10.9M$4.16M$280K$2M
Net cash provided by operating activities-$-162.44M-$-96.77M-$-76.38M-$-87.56M-$-84.89M
Investments in property, plant and equipment-$-290K-$-290K-$-190K-$-250K-$-750K
Acquisitions, net$0.00$0.00$0.00-$-1.31M-$-4.82M
Net cash used for investing activities$61.6M-$-20.61M-$-950K$1.06M$4.07M
Common stock issued$41.8M$151.2M$67.4M$1.35M-$-80K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$39.9M$194.6M$116.9M$97.1M$72.3M
Net change in cash-$-60.97M$77.2M$39.6M$10.6M-$-8.5M
Cash at end of period$112.1M$173.1M$95.8M$56.2M$45.6M
Operating cash flow-$-162.44M-$-96.77M-$-76.38M-$-87.56M-$-84.89M
Capital expenditure-$-290K-$-290K-$-190K-$-250K-$-750K
Free cash flow-$-162.73M-$-97.06M-$-76.57M-$-87.81M-$-85.64M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About UroGen Pharma Ltd.

        UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.

        CEO
        Elizabeth Barrett
        Employees
        291
        Beta
        1.57

        Explore

        Frequently asked questions

        What is the intrinsic value of UroGen Pharma Ltd. (URGN)?

        UroGen Pharma Ltd. (URGN) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is URGN undervalued?

        URGN trades at a price of $27.65 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.